Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chamberlain, M. C.
Right arrow Articles by Groshen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chamberlain, M. C.
Right arrow Articles by Groshen, S.
Related Collections
Right arrow All Oncology
Right arrow Metastatic tumor
NEUROLOGY 2004;63:2159-2161
© 2004 American Academy of Neurology
Brief Communications

Neoplastic meningitis-related encephalopathy

Prognostic significance

Marc C. Chamberlain, MD, Denice Tsao-Wei, MS and Susan Groshen, PhD

From the Department of Preventive Medicine, USC/Norris Cancer Center, University of Southern California, Los Angeles.

Address correspondence and reprint requests to Dr. Marc C. Chamberlain, Moffitt Cancer Center and Research Institute, Neuro-Oncology Program, 12902 Magnolia Drive, Tampa, FL 33612-9497; e-mail: ChambeMC{at}moffitt.usf.edu

Two cohorts of 20 patients diagnosed with neoplastic meningitis (NM) with or without encephalopathy were matched with respect to age, sex, primary tumor, and performance status. Median survival was 10 weeks (range 6 to 20 weeks) in the cohort with NM-related encephalopathy compared to 24 weeks (range 8 to 40 weeks) in the cohort without NM-related encephalopathy (p < 0.001). NM-related encephalopathy is a clinical variable that predicts for poor survival in patients with NM.

Received April 4, 2004. Accepted in final form July 22, 2004.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
M. C. Chamberlain, S. K. Johnston, and M. J. Glantz
Neoplastic Meningitis-Related Prognostic Significance of the Karnofsky Performance Status
Arch Neurol, January 1, 2009; 66(1): 74 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. D. Groves, M. J. Glantz, M. C. Chamberlain, K. E. Baumgartner, C. A. Conrad, S. Hsu, J. S. Wefel, M. R. Gilbert, S. Ictech, K. U. Hunter, et al.
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
Neuro-oncol, April 1, 2008; 10(2): 208 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
L. Harstad, K. R. Hess, and M. D. Groves
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis
Neuro-oncol, January 1, 2008; 10(6): 1010 - 1018.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.